251 related articles for article (PubMed ID: 24281000)
21. miR-215 functions as a tumor suppressor in epithelial ovarian cancer through regulation of the X-chromosome-linked inhibitor of apoptosis.
Ge G; Zhang W; Niu L; Yan Y; Ren Y; Zou Y
Oncol Rep; 2016 Mar; 35(3):1816-22. PubMed ID: 26676658
[TBL] [Abstract][Full Text] [Related]
22. Restoration of paclitaxel resistance by CDK1 intervention in drug-resistant ovarian cancer.
Bae T; Weon KY; Lee JW; Eum KH; Kim S; Choi JW
Carcinogenesis; 2015 Dec; 36(12):1561-71. PubMed ID: 26442525
[TBL] [Abstract][Full Text] [Related]
23. Elafin selectively regulates the sensitivity of ovarian cancer cells to genotoxic drug-induced apoptosis.
Wei H; Hellström KE; Hellström I
Gynecol Oncol; 2012 Jun; 125(3):727-33. PubMed ID: 22430613
[TBL] [Abstract][Full Text] [Related]
24. Molecular Effects of Doxorubicin on Choline Metabolism in Breast Cancer.
Cheng M; Rizwan A; Jiang L; Bhujwalla ZM; Glunde K
Neoplasia; 2017 Aug; 19(8):617-627. PubMed ID: 28654865
[TBL] [Abstract][Full Text] [Related]
25. Interplay of choline metabolites and genes in patient-derived breast cancer xenografts.
Grinde MT; Skrbo N; Moestue SA; Rødland EA; Borgan E; Kristian A; Sitter B; Bathen TF; Børresen-Dale AL; Mælandsmo GM; Engebraaten O; Sørlie T; Marangoni E; Gribbestad IS
Breast Cancer Res; 2014 Jan; 16(1):R5. PubMed ID: 24447408
[TBL] [Abstract][Full Text] [Related]
26. In vivo loss-of-function screens identify KPNB1 as a new druggable oncogene in epithelial ovarian cancer.
Kodama M; Kodama T; Newberg JY; Katayama H; Kobayashi M; Hanash SM; Yoshihara K; Wei Z; Tien JC; Rangel R; Hashimoto K; Mabuchi S; Sawada K; Kimura T; Copeland NG; Jenkins NA
Proc Natl Acad Sci U S A; 2017 Aug; 114(35):E7301-E7310. PubMed ID: 28811376
[TBL] [Abstract][Full Text] [Related]
27. Choline kinase alpha impairment overcomes TRAIL resistance in ovarian cancer cells.
Rizzo A; Satta A; Garrone G; Cavalleri A; Napoli A; Raspagliesi F; Figini M; De Cecco L; Iorio E; Tomassetti A; Mezzanzanica D; Bagnoli M
J Exp Clin Cancer Res; 2021 Jan; 40(1):5. PubMed ID: 33390181
[TBL] [Abstract][Full Text] [Related]
28. MicroRNA-145 targets TRIM2 and exerts tumor-suppressing functions in epithelial ovarian cancer.
Chen X; Dong C; Law PT; Chan MT; Su Z; Wang S; Wu WK; Xu H
Gynecol Oncol; 2015 Dec; 139(3):513-9. PubMed ID: 26472353
[TBL] [Abstract][Full Text] [Related]
29. Suppression of the grainyhead transcription factor 2 gene (GRHL2) inhibits the proliferation, migration, invasion and mediates cell cycle arrest of ovarian cancer cells.
Faddaoui A; Sheta R; Bachvarova M; Plante M; Gregoire J; Renaud MC; Sebastianelli A; Gobeil S; Morin C; Ghani K; Bachvarov D
Cell Cycle; 2017 Apr; 16(7):693-706. PubMed ID: 28278050
[TBL] [Abstract][Full Text] [Related]
30. Epithelial protein lost in neoplasm-α (EPLIN-α) is a potential prognostic marker for the progression of epithelial ovarian cancer.
Liu R; Martin TA; Jordan NJ; Ruge F; Ye L; Jiang WG
Int J Oncol; 2016 Jun; 48(6):2488-96. PubMed ID: 27035883
[TBL] [Abstract][Full Text] [Related]
31. In vivo detection of dysregulated choline metabolism in paclitaxel-resistant ovarian cancers with proton magnetic resonance spectroscopy.
Lu J; Li Y; Li YA; Wang L; Zeng AR; Ma XL; Qiang JW
J Transl Med; 2022 Feb; 20(1):92. PubMed ID: 35168606
[TBL] [Abstract][Full Text] [Related]
32. Overexpression of CD157 contributes to epithelial ovarian cancer progression by promoting mesenchymal differentiation.
Morone S; Lo-Buono N; Parrotta R; Giacomino A; Nacci G; Brusco A; Larionov A; Ostano P; Mello-Grand M; Chiorino G; Ortolan E; Funaro A
PLoS One; 2012; 7(8):e43649. PubMed ID: 22916288
[TBL] [Abstract][Full Text] [Related]
33. Choline kinase: an important target for cancer.
Janardhan S; Srivani P; Sastry GN
Curr Med Chem; 2006; 13(10):1169-86. PubMed ID: 16719778
[TBL] [Abstract][Full Text] [Related]
34. Tribbles 2 mediates cisplatin sensitivity and DNA damage response in epithelial ovarian cancer.
Kritsch D; Hoffmann F; Steinbach D; Jansen L; Mary Photini S; Gajda M; Mosig AS; Sonnemann J; Peters S; Melnikova M; Thomale J; Dürst M; Runnebaum IB; Häfner N
Int J Cancer; 2017 Oct; 141(8):1600-1614. PubMed ID: 28670762
[TBL] [Abstract][Full Text] [Related]
35. Malignant ascites enhances migratory and invasive properties of ovarian cancer cells with membrane bound IL-6R in vitro.
Kim S; Gwak H; Kim HS; Kim B; Dhanasekaran DN; Song YS
Oncotarget; 2016 Dec; 7(50):83148-83159. PubMed ID: 27825119
[TBL] [Abstract][Full Text] [Related]
36. The RUNX1 transcription factor is expressed in serous epithelial ovarian carcinoma and contributes to cell proliferation, migration and invasion.
Keita M; Bachvarova M; Morin C; Plante M; Gregoire J; Renaud MC; Sebastianelli A; Trinh XB; Bachvarov D
Cell Cycle; 2013 Mar; 12(6):972-86. PubMed ID: 23442798
[TBL] [Abstract][Full Text] [Related]
37. A Synthetic Lethality Screen Using a Focused siRNA Library to Identify Sensitizers to Dasatinib Therapy for the Treatment of Epithelial Ovarian Cancer.
Pathak HB; Zhou Y; Sethi G; Hirst J; Schilder RJ; Golemis EA; Godwin AK
PLoS One; 2015; 10(12):e0144126. PubMed ID: 26637171
[TBL] [Abstract][Full Text] [Related]
38. Characterization of DOK1, a candidate tumor suppressor gene, in epithelial ovarian cancer.
Mercier PL; Bachvarova M; Plante M; Gregoire J; Renaud MC; Ghani K; Têtu B; Bairati I; Bachvarov D
Mol Oncol; 2011 Oct; 5(5):438-53. PubMed ID: 21856257
[TBL] [Abstract][Full Text] [Related]
39. 4-Acetylantroquinonol B suppresses autophagic flux and improves cisplatin sensitivity in highly aggressive epithelial cancer through the PI3K/Akt/mTOR/p70S6K signaling pathway.
Liu M; Bamodu OA; Huang WC; Zucha MA; Lin YK; Wu ATH; Huang CC; Lee WH; Yuan CC; Hsiao M; Deng L; Tzeng YM; Yeh CT
Toxicol Appl Pharmacol; 2017 Jun; 325():48-60. PubMed ID: 28408137
[TBL] [Abstract][Full Text] [Related]
40. MicroRNA‑455 inhibits cell proliferation and invasion of epithelial ovarian cancer by directly targeting Notch1.
Xu L; Li H; Su L; Lu Q; Liu Z
Mol Med Rep; 2017 Dec; 16(6):9777-9785. PubMed ID: 29039517
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
